Eun Young Yang (executive director, head of the contract development operations, CDO, business team at Samsung BioLogics) speaking with BPI senior technical editor Cheryl Scott at September’s 2018 BPI Conference (Boston, MA).
Addressing manufacturing and technologies strategies to accelerate market entry is one of BPI’s highlighted themes for 2019. In partnership with our conference colleagues in Informa’s KNect365 division, this already has been a shared theme, reflecting the general goals of the industry and related advice from its regulators.
BPI’s summer 2018 preconference ebook included interviews by Dan Stanton (editor,
BioProcess Insider
) with speakers previewing their talks for the BPI Conference in Boston on 7 September 2018. Two of those conversations focused on ways their companies are reducing time to market. Then at the September event, a third interview on the theme was conducted by BPI’s senior technical editor, Cheryl Scott, at the BWB TV desk. Summaries are offered here, with
links to ...
schedl_b_and_w.jpg?width=100&auto=webp&quality=80&disable=upscale "Picture of Dan Stanton")
+1HTTPS://STOCK.ADOBE.COM
No matter what the industry, it’s widely accepted that slow-moving companies give their nimbler competitors an advantage, allowing them room to dominate the market even if their products are not superior. “Me-too” products and their sponsors often are seen as followers rather than leaders — even if they offer improvements over what is already available. Fast movers are flexible and adaptive to a dynamic business environment. They capitalize on opportunities and navigate risks and challenges by responding quickly to changes — or better yet, anticipating them. In some industries, speed can be achieved through supply chain compression, project management streamlining, automation, outsourcing, inventory control, and Internet/cloud-based collaborations. Some businesses even have the option of putting out “minimum viable products” just to get there first and then improving them for subsequent releases. Although some of those tactics may work in drug development to varying degrees, the la...
